IMR Press / RCM / Volume 7 / Issue S4 / pii/1561344069285-1978043716

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
The Relationship of Platelet Reactivity to the Occurrence of Post-Stenting Ischemic Events: Emergence of a New Cardiovascular Risk Factor
Show Less
1 Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD
Rev. Cardiovasc. Med. 2006, 7(S4), 20–28;
Published: 20 August 2006
Abstract
The reactivity of platelets to agonists plays a central role in the genesis of thrombosis following percutaneous coronary intervention (PCI) and spontaneous plaque rupture. Antiplatelet therapy has reduced the occurrence of thrombotic events following PCI, including myocardial infarction and stent thrombosis. Because the platelet is a fundamental component in the generation of an arterial thrombus and the stimulus for thrombosis is marked in PCI, it is logical to predict that patients with superior platelet inhibition would have the best outcomes with respect to ischemic events post PCI. However, until recently there was little information linking measurements of high ex vivo platelet reactivity to the occurrence of ischemic events. An emerging body of data, mostly from small studies, supports the pivotal link between periprocedural platelet physiology and increased risk of adverse thrombotic events. This review explores the available information linking platelet reactivity during and after PCI to the occurrence of adverse events, including myocardial infarction, recurrent ischemia within 6 months, and stent thrombosis.
Keywords
Platelet reactivity
Platelet aggregation
Platelet inhibition
Thrombosis
Share
Back to top